184 results for "Microdosing"
PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.
Pilot and feasibility studies – February 12, 2024
Summary
New research explores an innovative approach to easing end-of-life distress in advanced cancer patients by combining meaning-centered psychotherapy with low-dose psychedelics. The protocol examines whether microdosing lysergic acid diethylamide (LSD) alongside therapy can help reduce anxiety and depression. This groundbreaking New Zealand study includes both indigenous and non-indigenous participants, marking a culturally inclusive approach to mental health care.
Abstract
An advanced cancer diagnosis can be associated with a significant profile of distress. Psychedelic compounds have shown clinically significant effe...
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers.
Journal of psychopharmacology (Oxford, England) – April 18, 2025
Summary
A groundbreaking study reveals that microdosing LSD produces measurable effects in the body even at very low doses. Scientists tracked how the psychedelic compound moves through and affects the body (pharmacokinetics and pharmacodynamics) when taken sublingually. Results showed peak concentrations occur within 90 minutes, with subtle physiological changes lasting about 3 hours.
Abstract
Microdosing is the practice of taking psychedelic drugs at doses that produce no or minimal perceptible subjective or behavioural effects. This stu...
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
OpenAlex – February 23, 2026
Summary
Microdosing psilocybin shows promise as a treatment for major depressive disorder (MDD). In a clinical trial with 39 adults, both psilocybin and placebo groups experienced significant reductions in depressive symptoms after four weeks, with mean differences of -5.4 and -6.0 on the PHQ-9 scale, respectively. Notably, those starting with psilocybin reported greater symptom reduction on the Dysfunctional Attitudes Scale compared to the placebo group. Overall, psilocybin was safe and well tolerated, with no serious adverse effects reported during the study period.
Abstract
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant eff...
Global Drug Survey
OpenAlex – April 12, 2020
Summary
Microdosing Psilocybin and other psychedelics appears to offer substantial benefits, with 6,753 people reporting enhanced mood, creativity, and focus. In this large-scale Psychology and Pharmacology survey, the most common challenge associated with MicroDose practices was "none," suggesting minimal side-effects. While these hallucinogens, often products of chemical synthesis and alkaloids, show promise for Medicine, most individuals did not test their substances for purity, raising concerns in Drug Studies.
Abstract
Background: Microdosing psychedelics – the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushr...
Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial
OpenAlex – October 19, 2022
Summary
A large self-Blinding Clinical trial of 240 participants revealed that MicroDose tolerance develops for certain Psychedelics. Using a Placebo-controlled design, correct drug identification decreased by 0.017 with each dose, a key finding for Pharmacology. Post hoc analysis showed this tolerance was pronounced with LSD-analogues (often from chemical synthesis), dropping by 0.026 per dose. However, Psilocybin (an alkaloid) showed no such effect, suggesting its potential as a long-term Medicine. This insight into Neurotransmitter Receptor Influence on Behavior is vital for Drug Studies and the Psychology of microdosing.
Abstract
Microdosing is the practice of regularly using very low doses of psychedelic drugs. Anecdotal reports suggest that it may enhance well-being, creat...
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Scientific Reports – November 18, 2021
Summary
Among individuals with mental health concerns, microdosing psychedelics, primarily psilocybin (85% of users), correlates with lower reported levels of depression and anxiety. This finding emerged from a large psychological survey of 4050 microdosers and 4653 non-microdosers. The practice, often involving chemical synthesis and alkaloids, is gaining attention in clinical psychology and psychiatry as a potential avenue in medicine. These insights from psychedelics and drug studies highlight perceived mental health benefits, even though microdosers often report a history of mental health challenges.
Abstract
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on we...
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Scientific Reports – June 30, 2022
Summary
Microdosing the hallucinogen psilocybin shows promise for mental health. A 30-day observational study of 953 microdosers and 180 non-microdosers revealed small-to-medium improvements in mood and overall mental well-being, consistent across demographics. Older adults specifically experienced psychomotor performance gains. For older individuals, combining psilocybin with lion's mane and niacin further enhanced these psychomotor benefits, offering new insights for psychology, psychiatry, and clinical psychology. This contributes to pharmacology, psychedelic medicine, and complementary drug studies.
Abstract
Abstract Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regula...
Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers
OpenAlex – November 01, 2018
Summary
Microdosing psychedelics, like Psilocybin or Mescaline, shows exciting potential for mental health. In the first pre-registered study of its kind, individuals regularly consuming small, non-hallucinogenic doses scored higher on creativity, wisdom, and open-mindedness, while exhibiting less dysfunctional attitudes and negative emotionality than controls. This initial finding, relevant to Psychology and Clinical psychology, suggests a new paradigm for addressing anxiety and other mental health challenges. It offers a lower-risk approach than full-dose hallucinogen therapies, potentially informing future Psychiatry and Drug Studies without requiring a Psychotherapist for administration.
Abstract
Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in pop...
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
Frontiers in Psychiatry – September 13, 2019
Summary
Microdosing psychedelics shows greater self-rated effectiveness for mental health conditions like anxiety than conventional medicine. An online survey of 410 individuals found microdosing superior to prescribed treatments for both mental and physiological disorders. This offers insights for clinical psychology and psychiatry, exploring novel applications of psychedelic compounds. However, for anxiety and depression, full doses were rated more effective. This suggests potential for complementary medicine, prompting further drug studies into specific alkaloid compounds and their therapeutic use.
Abstract
Background: There is a growing interest in the use of psychedelic substances for health related purposes, including symptom relief for disorders li...
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
Sci Rep – July 28, 2022
Summary
Remarkable findings suggest microdosing psilocybin can significantly enhance mood and mental health. Individuals who regularly took small doses showed greater positive improvements in their emotional well-being over one month compared to those who did not. This indicates a promising link between microdosing and improved mental state, offering a potential avenue for boosting overall mood.
Abstract
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdos...
"O USO TERAPÊUTICO INDEPENDENTE DE MICRODOSAGEM DE PSILOCIBINA SOB PROTOCOLO FADIMAN : UM DIÁRIO DO AUTO-CONHECIMENTO"
Anais do 14º Congresso Brasileiro de Naturologia: Paradigmas contemporâneos da saúde mental e as novas perspectivas da medicina botânica – January 01, 2022
Summary
Could tiny doses of psilocybin unlock personal growth? A detailed self-report explored an individual's experience with a structured microdosing protocol. The compelling findings highlighted enhanced emotional regulation, improved focus, and profound insights into self-awareness, suggesting its potential as a tool for therapeutic self-discovery and overall well-being.
Abstract
A psilocibina é um composto psicodélico de ocorrência natural produzido por mais de 200 espécies de fungos. Os mais potentes são membros do gênero ...
Author response: Self-blinding citizen science to explore psychedelic microdosing
OpenAlex – December 11, 2020
Summary
Microdosing psychedelics like psilocybin offers no unique psychological benefits beyond expectation, a large clinical trial suggests. This self-blinding study, involving 191 participants over four weeks, found significant improvements in mood and anxiety for both microdose and placebo groups. Acute hallucinogen effects were observed but linked to participants breaking blind. This challenges anecdotal claims popular in clinical psychology, highlighting the potent placebo effect in medicine and addiction treatment. Findings influence future pharmacology, psychiatry, and drug studies concerning chemical synthesis.
Abstract
Article Figures and data Abstract eLife digest Introduction Materials and methods Results Discussion Appendix 1 Data availability References Decisi...
Tags
Psychedelic Microdosing among Young Adults from Southern California
Journal of Psychoactive Drugs – February 10, 2024
Summary
Nearly one in five young adults attempting psychedelic microdosing actually take standard, psychoactive doses, risking adverse effects. Among 2,396 young adults, only 3% (74 individuals) had ever microdosed, despite 12% awareness. Psilocybin (70%) and lysergic acid diethylamide (57%) were the most common hallucinogens. This underscores the need for Medicine, Psychiatry, and Psychology to provide clear guidance on these chemical synthesis and alkaloids, for both Clinical Psychology and broader Psychedelics and Drug Studies.
Abstract
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, an...
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention
Journal of Psychopharmacology – October 08, 2020
Summary
A survey of 6753 individuals reveals that reported benefits of Psilocybin and Lysergic acid diethylamide MicroDose practices overwhelmingly surpass challenges. Many users cite enhanced mood, creativity, and focus, with "None" being the most common challenge. However, most users do not test their substances, highlighting a gap in understanding chemical synthesis and alkaloids. Interestingly, an approach-intention in this Psychology-focused use of Hallucinogen substances predicted fewer benefits, hinting at potential Nocebo Effect mechanisms or complex Neurotransmitter Receptor Influence on Behavior. Future Pharmacology and Clinical psychology studies need rigorous Placebo-controlled designs for these Psychedelics and Drug Studies.
Abstract
Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containi...
Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
The primary care companion for CNS disorders – January 16, 2024
Summary
Regular microdosing of psychedelics like LSD and psilocybin shows promise for mental wellness, with users reporting improved mood and focus. Analysis of multiple studies reveals consistent benefits for daily functioning, though some participants experienced mild discomfort. Positive expectations often aligned with better outcomes in controlled trials.
Abstract
Objective: To investigate the relationship between psychedelic microdosing and its effects on mental health, aiming to understand if microdosing ca...
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Journal of Psychopharmacology – February 28, 2020
Summary
Individuals microdosing hallucinogens like psilocybin were significantly less likely to report anxiety disorders (OR = 0.61) or substance use disorders (OR = 0.17). A survey of 909 people explored the demographics of this population, with most using LSD (59.3%) or psilocybin (25.9%) at sub-hallucinogenic doses. While offering insights for psychiatry and potential medicine, these psychedelics and drug studies also found microdosers were over five times more likely (OR = 5.2) to use other recreational substances. Understanding these chemical synthesis alkaloids requires biochemical analysis.
Abstract
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gainin...
Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube
Harm Reduction Journal – November 28, 2019
Summary
Microdosing psychedelics, predominantly LSD and psilocybin, appears to offer significant therapeutic benefits, particularly for depression. A thematic analysis of online discussions reveals users report predominantly positive effects for various psychological and medical conditions. This applied psychology insight suggests microdosing, a practice within pharmacology and drug studies, provides a complementary approach, potentially mirroring full-dose benefits with reduced risks. Social interactions foster comprehension, offering strategies and emotional support. The user's intentions for engaging with these chemical synthesis and alkaloids significantly influence outcomes.
Abstract
Abstract Background Psychedelic microdosing is the trending practice of using tiny repeated doses of psychedelic substances to facilitate a range o...
A systematic study of microdosing psychedelics
PLoS ONE – February 06, 2019
Summary
Microdosing psychedelics, involving chemical synthesis and alkaloids, surprisingly correlates with increased Neuroticism, a personality trait relevant to Clinical psychology. An Observational study of 98 individuals, with 63 completing detailed measures, revealed reductions in reported depression and anxiety. However, daily Mood improvements were transient. Expectancy theory was explored with 263 participants, showing beliefs in broad benefits, which contrasted with the observed, limited effects on behavior. This highlights complexities for Medicine and Psychiatry regarding Neurotransmitter Receptor Influence.
Abstract
The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popul...
Motives and Side-Effects of Microdosing With Psychedelics Among Users
The International Journal of Neuropsychopharmacology – May 30, 2019
Summary
Many microdose psychedelics like psilocybin, hoping for a performance boost. A survey of 1116 users revealed 37% sought enhancement, often taking the hallucinogen 2-4 times weekly. While acute psychological side effects were common, the main reason for stopping was a lack of perceived effectiveness. This highlights the need for rigorous placebo-controlled medicine studies to understand the pharmacology of these chemical synthesis and alkaloids, and their neurotransmitter receptor influence on behavior, moving beyond anecdotal drug studies.
Abstract
Abstract Background Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especial...
Microdosing as a response to the meaning crisis
OpenAlex – May 26, 2020
Summary
Microdosing psychedelics can foster a profound sense of meaning and psychological flexibility, even if outcomes vary. Qualitative analysis of 118 responses showed individuals often use sub-hallucinogenic doses for clinical reasons, like mental health, or productivity. While some strongly endorse the practice, others experience disappointment, partly due to challenges with optimal dosing of these chemical substances. This growing area in drug studies suggests a deep psychological connection to meaning-making, potentially offering a vital sense of purpose.
Abstract
Background: The use of psychedelic substances like LSD and magic mushrooms in research and to treat mental health conditions has been increasing in...
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
Journal of Psychoactive Drugs – November 06, 2024
Summary
Exclusive psychedelic microdosers, a subset of 2488 individuals from a survey of 6193 consumers, exhibit distinct demographics and substance use patterns. They are older (46.4 vs. 42.0 years), predominantly female (68.4% vs. 44.7%), and report less non-psychedelic substance use (3.8 vs. 4.7 substances) compared to those also using macrodoses. Most microdose multiple times monthly, often with psilocybin (74.5%) or LSD (34.4%), primarily for wellbeing (73.0%), though 64.6% don't test their substances.
Abstract
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described t...
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
BMC psychiatry – March 14, 2023
Summary
Small doses of psychedelics like LSD and psilocybin may offer mental health benefits, according to users who carefully track their experiences. People who microdose report improved wellbeing, cognitive function, and social connections. They approach dosing methodically, often treating themselves as citizen scientists while documenting positive changes in mood and daily functioning.
Abstract
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that p...
Exploring the relationship between microdosing, personality and emotional insight: A prospective study
Journal of Psychedelic Studies – March 26, 2021
Summary
Microdosing psychedelics appears to shift fundamental aspects of Personality. Over 31 days, 24 individuals experienced increased Conscientiousness and decreased Neuroticism, suggesting these Big Five personality traits are not entirely stable. Among 76 baseline participants, Neuroticism linked to Alexithymia, a challenge in emotional awareness often relevant in Clinical psychology. Extraversion also positively correlated with microdosing experience, hinting at how these substances, often alkaloids from chemical synthesis, influence psychology. This area of Drug Studies may offer insights into brain disorders involving Tryptophan pathways.
Abstract
Abstract Backround and aims Having entered the recent public and research zeitgeist, microdosing involves consuming sub-perceptual doses of psyched...
Set and setting in microdosing: an oft-overlooked principle.
Psychopharmacology – December 01, 2022
Summary
Mindset and environment play a crucial role in how people respond to microdosing psychedelics like LSD and psilocybin. While most focus on dosage, research reveals that intention, expectations, and surroundings significantly influence outcomes. Understanding these "set and setting" factors helps explain varying results and could be key to optimizing the benefits of sub-perceptual doses.
Abstract
The use of psychedelics for medical and recreational purposes is rising. Contextual factors such as expectancy, intention, and sensory and social e...
Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
OpenAlex – June 14, 2021
Summary
Microdosing psilocybin, an alkaloid, subtly enhances creativity, specifically boosting originality in divergent thinking. A robust cognitive psychology investigation, pooling 175 participants across three double-blind placebo-controlled trials, found active microdosing increased the originality-to-fluency ratio in creative responses. While general cognition and mood weren't broadly affected, the quality of novel ideas improved, especially when relative dosage was considered. These psychedelics studies highlight the importance of controlling for expectation biases, suggesting effects are more nuanced than often claimed.
Abstract
Introduction: Microdosing refers to the repetitive administration of tiny doses of psychedelics (LSD, Psilocybin) over an extended period of time. ...
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study
Psychopharmacology – April 30, 2021
Summary
Participants in a study on psilocybin microdosing reported significantly heightened feelings of awe when exposed to engaging videos and abstract artworks. Out of 60 individuals, those who microdosed experienced a 30% increase in awe compared to the placebo group. However, nearly two-thirds of participants guessed their condition, indicating potential expectancy effects influencing their perceptions. This suggests that while psychedelics like psilocybin may enhance sensory experiences, expectations could play a crucial role in shaping these subjective benefits.
Abstract
Abstract There is an increased societal trend to engage in microdosing, in which small sub-hallucinogenic amounts of psychedelics are consumed on a...
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
Journal of Psychopharmacology – June 14, 2024
Summary
Microdosing psilocybin and other psychedelics appears to induce real changes in neurobiology, physiology, and cognition. This challenges claims these are merely placebo effects, driven by expectancy theory. A review of 19 placebo-controlled studies, despite often having small sample sizes, suggests genuine pharmacological influence. While not definitively ruling out a placebo, these drug studies in medicine and clinical psychology indicate hallucinogens, derived from chemical synthesis and alkaloids, warrant further exploration in complementary and alternative medicine.
Abstract
Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by e...
Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence
Premier journal of science. – December 03, 2024
Summary
Psilocybin microdosing shows promise for young adults struggling with anxiety, particularly those resistant to traditional therapies. This hallucinogen, an alkaloid, appears to improve mood and reduce anxiety symptoms, with some reports suggesting a 30-40% reduction in symptom severity. Its impact on psychology involves modulating serotonin receptors and boosting neural plasticity in brain regions crucial for emotional regulation. While clinical psychology and psychiatry explore these psychedelics, future drug studies might integrate digital mental health interventions, offering a compelling alternative for managing persistent anxiety.
Abstract
Background Anxiety disorders are increasingly prevalent among young adults. Traditional treatment options often fall short, and many patients live ...
Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide.
Psychopharmacology – February 01, 2025
Summary
New research challenges popular claims about microdosing LSD and creativity. While many people report feeling more creative when taking tiny amounts of psychedelics, this controlled study found no measurable improvements in either convergent or divergent thinking. Researchers tracked 80 participants taking low doses of lysergic acid diethylamide over six weeks, testing creative abilities through various tasks.
Abstract
Enhanced creativity is often cited as an effect of microdosing (taking repeated low doses of a psychedelic drug). There have been recent efforts to...
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
Pilot and feasibility studies – October 05, 2023
Summary
A groundbreaking trial explores microdosing with lysergic acid diethylamide (LSD) as a potential treatment for major depressive disorder. Twenty patients received tiny doses of LSD twice weekly for 8 weeks. The study found the treatment was generally well-tolerated, with high attendance rates and promising early signs of reduced depression symptoms.
Abstract
Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepress...
The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field
Neuroscience & Biobehavioral Reviews – May 09, 2025
Summary
Contrary to popular belief in human psychology, psychedelic microdosing showed minimal behavioral changes in animals. A review of 12 animal testing studies across rats, mice, and zebrafish found low doses of LSD, psilocybin, or DMT—synthesized alkaloids—generally caused little difference in anxiety- or depressive-like states. These pharmacology drug studies indicated the substances were well-tolerated by all three species. While brain chemistry, including nicotinic acetylcholine receptors, may be subtly affected, widespread benefits were not observed.
Abstract
Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is...
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
Trials – August 24, 2024
Summary
A groundbreaking trial explores microdosing LSD as a potential treatment for major depressive disorder. This first-of-its-kind randomized controlled trial will test sub-hallucinogenic doses of psychedelics, with participants taking small amounts twice weekly at home. The 8-week study measures mood improvements while carefully monitoring safety and effectiveness through brain activity, blood markers, and sleep patterns.
Abstract
Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable sid...
Exploring Microdosing Psychedelics as a Self-Managed Treatment for Premenstrual Dysphoric Disorder: A Qualitative Study
OpenAlex – July 25, 2025
Summary
All 14 individuals interviewed about managing Premenstrual dysphoric disorder (PMDD) reported benefits from microdosing psilocybin. This qualitative research, exploring experiences from a clinical psychology and psychiatry perspective, revealed striking positive outcomes. People are self-medicating with psychedelics, often without psychotherapist guidance, to alleviate severe PMDD symptoms. While regimen varied, every participant found relief. This area of Psychology and Psychedelics and Drug Studies suggests a potential for new treatments, inspiring future investigations akin to herbal medicine research studies.
Abstract
Background: Premenstrual dysphoric disorder (PMDD) is a severe mood disorder characterised by depression, irritability, mood lability, anxiety and ...
A Novel Stability Indicating High Performance Liquid Chromatography Method for Lysergic Acid Diethylamide Quantification: From Microdosing Applications to Broader Analytical Use.
Journal of chromatographic science – November 15, 2025
Summary
Many microdosing LSD users might be taking vastly different doses than intended. A robust new method was developed to precisely quantify lysergic acid diethylamide, even separating it from degradation products. This high-performance liquid chromatography (HPLC) technique was rigorously validated, proving effective under stress. Applied to community samples, a significant discrepancy emerged between user-estimated and actual LSD levels. This advancement offers crucial tools for safety and quality control in both clinical and illicit LSD formulations, underscoring risks of unregulated products.
Abstract
With the rising interest in therapeutic potential of microdosing lysergic acid diethylamide (LSD), accurate quantification and stability analysis a...
“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics
Journal of Drug Issues – October 31, 2025
Summary
Microdosing psychedelics, including psilocybin and LSD, is rapidly gaining popularity for its perceived self-enhancing benefits rather than euphoric experiences. Interviews with 200 active microdosers reveal that 85% report improved wellbeing, with many using it to aid abstinence from more harmful substances. Participants cite motivations ranging from alleviating anxiety and depression to enhancing creativity and focus. This novel approach distinguishes itself sharply from traditional substance use, making microdosing one of the fastest-growing trends in contemporary illicit drug consumption.
Abstract
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and ...
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study
Journal of Psychopharmacology – December 17, 2021
Summary
Despite popular belief, a rigorous double-blind, placebo-controlled crossover study revealed that microdosing the hallucinogen psilocybin for three weeks did not alleviate anxiety or depression symptoms. This research in clinical psychology, exploring how psychedelics, specifically this chemical synthesis alkaloid, influence behavior and affect, found no significant changes in emotion processing. The findings challenge anecdotal reports suggesting psilocybin's broad benefits, indicating its neurotransmitter receptor influence might not translate to these particular psychological improvements in a microdosing context. Psychiatry may need to re-evaluate common assumptions.
Abstract
Background: Microdoses of psychedelics (i.e. a sub-hallucinogenic dose taken every third day) can reduce symptoms of depression, anxiety and stress...
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Transcultural Psychiatry – August 29, 2022
Summary
Microdosing classical hallucinogens like Psilocybin and Lysergic acid diethylamide is a burgeoning trend, despite limited formal drug studies. While macrodosing effects are well-documented, microdosing involves intermittent, sub-perceptual doses, reportedly enhancing cognition and mental function. Many claim it's a therapeutic intervention, improving psychology without full "trips." This exploration synthesizes the social and clinical context of this practice, examining its potential as a psychotherapist-guided tool versus recreational use. Understanding these substances, often products of chemical synthesis, requires biochemical analysis to discern their true impact.
Abstract
To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD)...
Microdosing psychedelics has no impact on cognitive function in naturalistic settings
Journal of Psychology & Clinical Psychiatry – August 01, 2023
Summary
Microdosing psychedelics does not objectively enhance neurocognitive performance, challenging popular belief. An observational study of 17 participants found no improved cognition—including processing speed, attention, or memory—on microdosing days or the day after. This suggests perceived benefits stem from psychological rather than direct neurocognitive pathways, offering insights for cognitive psychology. These Drug Studies highlight the complex interplay of perception and actual performance, distinct from biochemical effects, unlike factors such as sleep deprivation.
Abstract
Background and aim: Subjective and anecdotal accounts link ingestion of psychedelic microdoses, quantities small enough to retain perceptual clarit...
No evidence that LSD microdosing affects recall or the balance between distracter resistance and updating
bioRxiv Preprint Server – December 02, 2021
Summary
Could microdosing LSD sharpen your mind? A recent investigation explored whether tiny doses (5-20 µg) of LSD impact working memory—our ability to recall information and manage distractions. Participants in a controlled setting received either a microdose or a placebo, then completed tasks designed to test memory recall and the processing of new information. The results showed no evidence that these small doses improved memory accuracy or efficiency, nor did they alter how individuals handle distractions versus updating their memory. This suggests microdosing may not provide the cognitive boost some expect.
Abstract
The effect of low doses (<=20 μg) of LSD on working memory, in the absence of altered states of consciousness, remain largely unexplored. Given its...
Accounting for Microdosing Classic Psychedelics
Journal of Drug Issues – August 30, 2019
Summary
Remarkably, individuals who microdose psychedelics, like chemically synthesized LSD and natural psilocybin, never excuse their practice. All 30 interviewed offered justifications, a key insight for Social psychology. This Psychology research shows users employ "Denial of injury" and "Appeal to normality" to align their actions with societal expectations, even considering the substances' status in Drug Studies and potential for Forensic Toxicology.
Abstract
Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substance...
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Translational Psychiatry – August 02, 2022
Summary
Low doses of psilocybin mushrooms can produce noticeable subjective effects, yet they may not enhance creativity or cognitive function. In a study with 34 participants, those who received 0.5 g of dried mushrooms reported significantly more intense experiences than those on a placebo—only if they identified their condition correctly. EEG analysis revealed reduced theta band power but no substantial cognitive improvements; instead, some individuals exhibited slight cognitive impairment. These findings suggest that expectations might drive the perceived benefits of microdosing rather than the substance itself.
Abstract
Abstract The use of low sub-perceptual doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports clai...
Natural language signatures of psilocybin microdosing
OpenAlex – February 22, 2022
Summary
Artificial intelligence can accurately detect a psilocybin microdose from speech. A double-blind, placebo-controlled experiment explored how this hallucinogen, a chemical synthesis and alkaloid, affects natural language. Participants received either a 0.5g psilocybin mushroom microdose or a placebo. Analyzing speech for verbosity, semantic variability, and sentiment scores, differences emerged in all but semantic variability. Computer science techniques, specifically machine learning, then distinguished between conditions with high accuracy (AUC≈0.8). This breakthrough in psychology and pharmacology offers new biochemical analysis for psychedelics and drug studies, potentially monitoring microdosing schedules.
Abstract
Abstract Serotonergic psychedelics are being studied as novel treatments for mental health disorders and as facilitators of improved well-being, me...
LSD increases sleep duration the night after microdosing.
Translational psychiatry – April 15, 2024
Summary
A groundbreaking discovery shows that tiny amounts of LSD can naturally extend sleep duration. When healthy adults took small, non-hallucinogenic doses every third day, they slept an average of 24 minutes longer the following night. The six-week study tracked over 3,000 nights of sleep, revealing consistent improvements without affecting sleep quality or daily activity levels. These results suggest microdosing could offer a novel approach to sleep enhancement.
Abstract
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the ef...
Microdosing psychedelics in the treatment of ADHD and comorbid disorders
European Psychiatry – April 01, 2024
Summary
Many individuals with ADHD report microdosing psychedelics offers more symptom relief than conventional treatments. A naturalistic study of people with ADHD over four weeks revealed reduced symptoms, increased trait mindfulness, and decreased neuroticism. These findings suggest microdosing, involving small doses of substances like LSD or psilocybin (from chemical synthesis and alkaloids), holds promise for Psychiatry and Psychology. It could potentially serve as a maintenance therapy, aiding those for whom full psychedelic doses are unsuitable. Ongoing clinical trials will further explore these intriguing effects.
Abstract
Abstract Microdosing psychedelics has garnered considerable attention within both nonprofessional circles and the scientific community in recent ye...
Keeping the promise: a critique of the current state of microdosing research
Frontiers in Psychiatry – February 05, 2024
Summary
Despite widespread interest in microdosing psychedelics for improved mood and creativity, a critical review of 15 papers concludes existing research quality is insufficient for drawing firm conclusions. Claims of psychological or medical benefits lack robust scientific backing. The field of Psychedelics and Drug Studies requires more rigorous methodology, reflecting the careful design principles seen in Engineering ethics, before efficacy or safety can be confirmed. Understanding the true impact of these chemical synthesis-derived alkaloids on human experience demands higher quality studies.
Abstract
Introduction The practice of taking small, sub-hallucinogenic doses of psychedelics, known as microdosing, has exploded in popularity over the last...
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
Journal of Psychopharmacology – January 12, 2024
Summary
Microdosing psychedelics, popular in psychology, carries unknown long-term cardiac health risks. Regular use, often 2-4 times weekly for months or years, raises a significant medical concern. Compounds like LSD and psilocybin structurally resemble drugs known to cause cardiac fibrosis and valvulopathy, a critical issue in internal medicine. This risk stems from their neurotransmitter receptor influence on behavior, specifically the 5-HT2B receptor. Understanding these effects is crucial for future Psychedelics and Drug Studies and informs physical medicine.
Abstract
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly ...
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
Journal of Psychopharmacology – July 14, 2019
Summary
Despite widespread claims that microdosing psychedelics, like the alkaloid psilocybin, enhances mood and cognition, scientific understanding remains critically underdeveloped. A review in Psychology and Drug Studies stresses the urgent need for rigorous Pharmacology research, employing biochemical analysis and sensing techniques to quantify both positive and potential negative effects. Future Medicine must move beyond anecdotes, investigating the full impact of these low-dose hallucinogens on biological and cognitive parameters, including risks.
Abstract
Background: In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been mad...
Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity
OpenAlex – December 07, 2021
Summary
The perceived benefits of microdosing psilocybin, a potent hallucinogen, might largely stem from expectation. In a double-blind, placebo-controlled investigation, 34 individuals received either 0.5g dried *Psilocybe cubensis* or a placebo. While acute subjective effects were more intense with the active dose (likely due to unblinding), measurements of cognition, perception, and creativity showed null effects or even trends towards impairment. This pharmacology research, crucial for Psychedelics and Drug Studies, suggests psychology's role in perceived outcomes, challenging many claims within Complementary and Alternative Medicine Studies.
Abstract
Abstract The use of low sub-hallucinogenic doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports ...
Salience, Sensemaking, and Setting in Psilocybin Microdosing: Methodological Lessons and Preliminary Findings of a Mixed Method Qualitative Study
OpenAlex – March 20, 2024
Summary
Momentary experiences of psilocybin microdosing often contradict retrospective accounts, revealing a complex psychological landscape. This qualitative research, part of broader psychedelics and drug studies, found individuals report loosened mental structures and increased external salience. Such shifts in sensemaking and perception, impacting flexible and stable cognition, could significantly alter behavior. Understanding these effects is crucial, as changes in psychological processing could influence decision-making, including aspects related to drug use or sexual risk, within an individual's broader existential context.
Abstract
There are profound methodological challenges facing microdosing research. One way we can address some of these methodological issues is by understa...
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
Biological psychiatry – September 15, 2023
Summary
Small doses of LSD taken every three days improved daily well-being, creativity, and mood in healthy volunteers. In this home-based trial, participants who microdosed reported feeling more connected, energetic, and happy on dosing days, though some experienced anxiety. While these mood boosts were temporary, the study shows LSD microdosing is generally safe and can enhance daily life.
Abstract
Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials ...
Psilocybin microdosing in the United States: Insights from a nationally representative survey
Addiction – March 08, 2026
Summary
Over 8.4 million US adults have tried microdosing psilocybin, with recent users more likely to report microdosing during their last experience compared to those who used it over a year ago. Notably, about 15% of respondents were uncertain if they microdosed the last time. The primary motivations for this practice include enhancing physical and mental health. This data, drawn from the National Health Interview Survey, highlights the growing interest in psychedelics within diverse fields like psychology, psychiatry, and environmental health.
Abstract
At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to...
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Journal of Psychopharmacology – August 12, 2023
Summary
Chronic microdosing of psychedelics like Lysergic acid diethylamide and Psilocybin may pose a heart valve risk. Pharmacology analysis of these hallucinogens, plus Mescaline and MDMA, revealed all five compounds bind to the serotonin 5-HT 2B receptor with equal or greater potency than their primary targets. While safety pharmacology margins for typical microdoses are better than known heart-damaging agents, a potential risk remains. Forensic Toxicology and Drug Analysis show MDMA's link to valvular heart disease at full doses. This insight into neurotransmitter receptor influence on behavior informs future drug studies and medicine.
Abstract
Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term s...
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
Journal of psychoactive drugs – January 01, 2019
Summary
Albert Hoffman's idea that low-dose LSD could be a Ritalin alternative sparked interest in microdosing. An exploration involving over a thousand individuals globally found that regular, small amounts of psychedelics, around 10 micrograms, were widely considered safe. Participants reported significant improvements in mood, energy, and work effectiveness. Many also noted better health habits and relief from conditions like migraines and depression, suggesting notable benefits from microdosing.
Abstract
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration...
Less is more? A review of psilocybin microdosing
Journal of Psychopharmacology – September 16, 2024
Summary
Definitive conclusions on psilocybin microdosing, a hallucinogen derived from alkaloids, remain elusive despite its potential in Medicine. A review of 40 studies and 8 grey literature websites, found via databases like MEDLINE, reveals a critical lack of robust evidence in Clinical psychology. Most findings stem from observational studies, with sparse clinical trials. Future Psychedelics and Drug Studies must address these gaps, including dose-response and psychological testing, to validate psilocybin's use as a Complementary and Alternative Medicine.
Abstract
Background: The applications of psilocybin, derived from ‘magic mushrooms,’ are vast, including a burgeoning practice known as microdosing, which r...
Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.
BMC neuroscience – February 05, 2024
Summary
Tiny doses of lysergic acid diethylamide (LSD) may subtly rewire brain connections, revealed through advanced brain imaging. This groundbreaking research tracked neuroplasticity changes in 80 healthy men using dynamic causal modelling, showing how microdoses affect neural pathways and long-term potentiation in visual processing areas, particularly in specific brain layers.
Abstract
Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have...
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Scientific Reports – January 21, 2021
Summary
After four weeks, 81 individuals microdosing psychedelics reported improved mood, reduced anxiety, and enhanced mental health, reaching a key clinical endpoint. However, this prospective study, relevant to clinical psychology and psychiatry, revealed that positive expectancy at baseline strongly predicted these benefits, suggesting a significant placebo response. While prior observational studies hinted at benefits in complementary medicine, these drug studies highlight psychology's role via expectancy theory, cautioning against overstating direct medicinal value.
Abstract
Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports a...
Microdosing of Psychoactive Substances in Business Practice
Businesses – December 06, 2021
Summary
Remarkably, microdosing **drugs of abuse** like LSD and cocaine allows individuals to sustain a subtle psychoactive effect through the work week, avoiding significant behavioral changes or withdrawal. This **dosing** strategy, unlike standard use, even sees stimulants require progressively lower doses over time for the same effect, a fascinating **pharmacology** insight. Conversely, **psychedelics** develop resistance. Through **case studies** examining **psychology** and initial **biochemical analysis** in corporate environments, this approach's influence on business managers and creatives is being explored, revealing a unique pattern of substance interaction.
Abstract
Abusing psychoactive substances has been a popular sport in the business world since the mid-19th century. First, they were appreciated for their s...
Microdosing Psychedelics: Current Evidence From Controlled Studies.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Regular, tiny doses of lysergic acid diethylamide (LSD) can produce subtle but measurable effects on mood, pain perception, and social awareness without serious side effects. Controlled research shows that microdosing psychedelics at 10-20 micrograms affects blood pressure and brain connectivity while remaining safe. Lower doses of 5 micrograms showed no noticeable effects.
Abstract
Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential ps...
The therapeutic potential of microdosing psychedelics in depression
Therapeutic Advances in Psychopharmacology – January 01, 2020
Summary
Microdosing psychedelics like LSD and psilocybin shows subtle cognitive benefits, potentially offering new avenues for depression treatment. A review of 14 experimental drug studies found small doses (e.g., 10-20 mcg LSD) subtly improve thinking and affect brain regions. While generally well-tolerated with minimal physiological impact, some users experience increased anxiety or mood cycling. These pharmacological effects suggest microdosing could foster cognitive flexibility, potentially reducing rumination—a key aspect of psychological distress. Understanding its therapeutic value as an alternative psychiatric approach warrants continued medical inquiry.
Abstract
Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few w...
Is Microdosing a Placebo?
OpenAlex – June 04, 2023
Summary
The idea that microdosing psychedelics is merely a Placebo effect is likely premature. While Expectancy theory plays a role in Psychology, evidence from Psychedelics Drug Studies suggests Dose dependence, challenging a purely psychological explanation. Existing Pharmacology research often features small sample sizes and limited dose ranges, making definitive conclusions difficult. The measured impact of expectancy is also often small, and Selection bias can influence results. It's currently impossible to definitively state whether microdosing's benefits are solely a Placebo effect, suggesting complex interactions in Medicine.
Abstract
Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by e...